The development of bis(hydroxymethyl)pyrrole analogs as bifunctional DNA cross-linking agents and their chemotherapeutic potential

European Journal of Medicinal Chemistry

Volumn 69, Issue , 2013, Pages 609-621

  Su, Tsann Long ^a   Lee, Te Chang ^a   Kakadiya, Rajesh ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Antitumor agents; Bifunctional; Bis(hydroxymethyl) pyrroles; Cytotoxicity; DNA cross linking agents; Hybrid pharmacophore; Indolizino 67 b indole

Indexed keywords

1 PHENYL 2,5 DIMETHYL 3,4 BIS(HYDROXYMETHYL)PYRROLE; 2 PHENYL 1 METHYL 3,4 BIS(HYDROXYMETHYL)PYRROLE; 2,3 DIHYDROXY 6,7 BIS(HYDROXYMETHYL)PYRROLIZINE DERIVATIVE; 2,3 DIPHENYL 2,5 DIMETHYL 3,4 BIS(HYDROXYMETHYL)PYRROLE; 4,5 BIS(HYDROXYMETHYL)IMIDAZOLE DERIVATIVE; 5 (3,4 DICHLOROPHENYL) 2,3 DIHYDRO 6,7 BIS(HYDROXYMETHYL) 1H PYRROLIZINE BIS(N ISOPROPYL)CARBAMATE; 6,7 BIS(HYDROXYMETHYL)PYRROLO[1,2 C]THIAZOLE; 8 METHOXY 3 METHYL 4,5 DIHYDROPYRROLO[2,1 A ]ISOQUINOLINE; ANTIINFECTIVE AGENT; ANTILEUKEMIC AGENT; ARSENIC TRIOXIDE; BIS(HYDROXYMETHYL) 5,10 DIHYDROPYRROLO[1,2 B]ISOQUINOLINE DERIVATIVE; BIS(HYDROXYMETHYL) 9H PYRROLO[1,2 A]INDOLE 1,2 DIYLS; BIS(HYDROXYMETHYL)BENZO[D]PYRROLO[2,1 B]THIAZOLE DERIVATIVE; BIS(HYDROXYMETHYL)PYRROLE DERIVATIVE; CARMETHIZOLE; CISPLATIN; DIHYDROPYRROLO[2,1 B]THIAZOLE; INDOLIZINO[6,7 B]INDOLE DERIVATIVE; MELPHALAN; MITOMYCIN; PACLITAXEL; PYRROLE DERIVATIVE; PYRROLIZIDINE ALKALOID; PYRROLIZINE DERIVATIVE; PYRROLO[1,2 A]QUINOLINE DERIVATIVE; PYRROLO[2,1 A]ISOQUINOLINE DERIVATIVE; THIOTEPA; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLON ADENOCARCINOMA; CROSS RESISTANCE; DNA CROSS LINKING; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; ELECTROPHILICITY; HUMAN; LIPOPHILICITY; LYMPHATIC LEUKEMIA; MELANOMA B16; MOUTH CANCER; NONHUMAN; NUCLEOPHILICITY; OVARY ADENOCARCINOMA; PROSTATE ADENOCARCINOMA; REVIEW; STRUCTURE ACTIVITY RELATION;

(2,3-DIHYDRO-5-(3′,4′-DICHLOROPHENYL)-6,7-BIS(HYDROXYMETHYL)-1H-PYRROLIZINE BIS(ISO-PROPYLCARBAMATE); ANTITUMOR AGENTS; ARSENIC TRIOXIDE; ATO; BIFUNCTIONAL DNA CROSS-LINKING AGENTS; BIS(HYDROXYMETHYL)PYRROLES; COMPLETE TUMOR REMISSION; CR; CYTOTOXICITY; DHP; DIHYDROPYRROLIZINE ALCOHOL; DIMETHYL ACETYLENEDICARBOXYLATE; DMAD; DNA DOUBLE-STRAND BREAK; DNA-DEPENDENT PROTEIN KINASE; DNA-PK; DSB; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PHARMACOPHORE; INDOLIZINO[6,7-B]INDOLE; INTRAPERITONEAL INJECTION; INTRAVENOUS INJECTION; IP INJ.; IPP; IV INJ.; MAXIMUM TOLERATED DOSE; MDR; MITOMYCIN C; MMC; MTD; MULTIDRUG-RESISTANT; P-GLYCOPROTEIN; P-GP; PARP; POLY ADP-RIBOSE POLYMERASE; SARS; STRUCTURE-ACTIVITY RELATIONSHIPS; TOPO I; TOPO II; TOPOISOMERASE I; TOPOISOMERASE II;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-LINKING REAGENTS; DNA; DNA REPAIR; HUMANS; PYRROLES; PYRROLIDINES;

EID: 84884798994     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.09.016     Document Type: Short Survey

References (59)

1. S.R. Rajski, and R.M. Williams DNA cross-linking agents as antitumor drugs Chem. Rev. 98 1998 2723 2795 (Pubitemid 128620332)
2. O.D. Schärer DNA interstrand crosslinks: natural and drug-induced DNA adducts that induce unique cellular responses ChemBioChem 6 2005 27 32 (Pubitemid 40128631)
3. L. Brulikova, J. Hlavac, and P. Hradil DNA interstrand cross-linking agents and their chemotherapeutic potential Curr. Med. Chem. 19 2012 364 385
4. W.K. Anderson, and P.F. Corey Synthesis and antileukemic activity of 5-substituted 2,3-dihydro-6,7-bis(hydroxymethyl)-1H-pyrrolizine diesters J. Med. Chem. 20 1977 812 818 (Pubitemid 8096811)
5. W.K. Anderson, and H.L. McPherson Jr. Synthesis and antileukemic activity of fluorinated analogues of 2,3-dihydro-5-phenyl-6,7-bis(hydroxymethyl)-1H- pyrrolizine biscarbamate J. Med. Chem. 25 1982 84 86 (Pubitemid 12132099)
6. W.K. Anderson, J.S. New, and P.F. Corey Vinylogous carbinolamine tumor inhibitors. 7. Tumor inhibitory agents: bis-(N-alkylcarbamate) derivatives of 2,3-dihydro-5-(3′,4′-dichlorophenyl)-6,7-bis(hydroxymethyl) -1H-pyrrolizine Arzneimittelforschung 30 1980 765 767 (Pubitemid 10107309)
7. W.K. Anderson, C.P. Chang, and H.L. McPherson Jr. Synthesis, evaluation of chemical reactivity, and murine antineoplastic activity of 2-hydroxy-5-(3,4-dichlorophenyl)-6,7-bis(hydroxymethyl)-2,3-dihydro-1H- pyrrolizine bis(2-propylcarbamate) and 2-acyloxy derivatives as potential water-soluble pro-drugs J. Med. Chem. 26 1983 1333 1338 (Pubitemid 13012816)
8. W.K. Anderson, D.C. Dean, and T. Endo Synthesis, chemistry, and antineoplastic activity of alpha-halopyridinium salts: potential pyridone prodrugs of acylated vinylogous carbinolamine tumor inhibitors J. Med. Chem. 33 1990 1667 1675 (Pubitemid 20180626)
9. W.K. Anderson, and R.H. Mach Vinylogous carbinolamine tumor inhibitors. 21. Synthesis, chemical reactivity, and antileukemic activity of 5-substituted 6,7-bis(hydroxymethyl)pyrrolo[1,2-c]thiazole biscarbamates and the corresponding sulfoxides and sulfones J. Med. Chem. 30 1987 2109 2115 (Pubitemid 18046072)
10. M.I. Soares, A.F. Brito, M. Laranjo, A.M. Abrantes, M.F. Botelho, J.A. Paixão, A.M. Beja, M.R. Silva, E. Pinho, and T.M. Melo Chiral 6-hydroxymethyl-1H,3H-pyrrolo-[1,2-c]thiazoles: novel antitumor DNA monoalkylating agents Eur. J. Med. Chem. 45 2010 4676 4681
11. I. Lalezari, and E.L. SchwartZ Synthesis and antineoplastic activity of 5-aryl-2,3-dihydropyrrolo[2,1-b]thiazole-6,7-dimethanol 6,7- bis(isopropylcarbamates) J. Med. Chem. 31 1988 1427 1429
12. W.K. Anderson, and P.F. Corey Antileukemic activity of derivatives of 1-phenyl-2,5-dimethyl-3,4-bis(hydroxymethyl)pyrrole bis(N-methylcarbamate) J. Med. Chem. 20 1977 1691 1694 (Pubitemid 8231455)
13. W.K. Anderson, and M.J. Halat Antileukemic activity of derivatives of 1,2-dimethyl-3,4-bis(hydroxymethyl)-5-phenylpyrrole bis(N-methylcarbamate) J. Med. Chem. 22 1979 977 980 (Pubitemid 10235936)
14. W.K. Anderson, M.J. Halat, and A.C. Rick Synthesis and antileukemic activity of 1-methyl-2,5-diphenyl-3,4-bis(hydroxymethyl)-, 1,2,3-triphenyl-4,5- bis(hydroxymethyl)-, and 1-methyl-2,3-diphenyl-4,5-bis(hydroxymethyl)pyrrole bis(N-methylcarbamate) J. Med. Chem. 23 1980 87 89 (Pubitemid 10192903)
15. W.K. Anderson, D. Bhattacharjee, and D.M. Houston Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole J. Med. Chem. 32 1989 119 127 (Pubitemid 19025298)
16. R. Kakadiya, H. Dong, P.C. Lee, N. Kapuriya, X. Zhang, T.C. Chou, T.C. Lee, K. Kapuriya, A. Shah, and T.L. Su Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a] indenes Bioorg. Med. Chem. 17 2009 5614 5626
17. R. Chaniyara, S. Tala, C.W. Chen, P.C. Lee, R. Kakadiya, H. Dong, B. Marvania, C.H. Chen, T.C. Chou, T.C. Lee, A. Shah, and T.L. Su Synthesis and antitumor evaluation of novel benzo[d]pyrrolo[2,1-b]thiazole derivatives Eur. J. Med. Chem. 53 2012 28 40
18. W.K. Anderson, H.L. McPherson Jr., J.S. New, and A.C. Rick Synthesis and murine antineoplastic activity of bis[(carbamoyloxy)methyl] derivatives of pyrrolo[2,1-a]isoquinoline J. Med. Chem. 27 1984 1321 1325 (Pubitemid 14032247)
19. W.K. Anderson, A.R. Heider, N. Raju, and J.A. Yucht Synthesis and antileukemic activity of bis[[(carbamoyl)oxy]methyl]-substituted pyrrolo[2,1-a]isoquinolines, pyrrolo[1,2-a]quinolines, pyrrolo[2,1-a] isobenzazepines, and pyrrolo[1,2-a]benzazepines J. Med. Chem. 31 1988 2097 2102
20. R. Chaniyara, N. Kapuriya, H. Dong, P.C. Lee, S. Suman, B. Marvania, T.C. Chou, T.C. Lee, R. Kakadiya, A. Shah, and T.L. Su Novel bifunctional alkylating agents, 5,10-dihydropyrrolo[1,2-b]isoquinoline derivatives, synthesis and biological activity Bioorg. Med. Chem. 19 2011 275 286
21. R. Chaniyara, S. Tala, C.W. Chen, X. Zang, R. Kakadiya, L.F. Lin, C.H. Chen, S.I. Chien, T.C. Chou, T.H. Tsai, T.C. Lee, A. Shah, and T.L. Su Novel antitumor indolizino[6,7-b]indoles with multi-mode of actions: DNA cross-linking and toposisomerases I and II inhibition J. Med. Chem. 56 2013 1544 1563
22. S.T. Crooke, and W.T. Bradner Mitomycin C: a review Cancer Treat. Rev. 3 1976 121 139
23. S.K. Carter, and S.T. Crooke Mitomycin C, Current Status and New Development 1978 Academic Press New York
24. G. Powis Metabolism and reactions of quinoid anticancer agents Pharmacol. Ther. 35 1987 57 162 (Pubitemid 18013042)
25. H.W. Moore, and R. Czerniak Naturally occurring quinones as potential bioreductive alkylating agents Med. Res. Rev. 1 1981 249 280 (Pubitemid 12039203)
26. R.W. Franck, and M. Tomasz The chemistry of mitomycins D.E.V. Wilman, Chemistry of Antitumor Agents 1990 Blackie & Son New York 379 394 (Chapter 15)
27. M. Tomaz, R. Lipman, D. Chowdary, J. Pawlak, G. Verdine, and K. Nakanishi Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA Science 235 1987 1204 1208 (Pubitemid 17034007)
28. A.K. Chawla, R. Lipman, and M. Tomasz Covalent crosslinks and monofunctional adducts of mitomycin C in the minor groove of DNA: effects on DNA conformation and dynamics R.H. Sharma, M.H. Sharma, Structure and Expression DNA and Its Drug Complexities vol. 2 1987 Adenine Press Guilderland, NY 305 316
29. H. Borowy-Borowski, R. Lipman, D. Chowdary, and M. Tomasz Duplex oligodeoxyribonucleotides cross-linked by mitomycin C at a single site: synthesis, properties, and cross-link reversibility Biochemistry 29 1990 2992 2999 (Pubitemid 20119295)
30. S.P. Teng, S.A. Woodson, and D.M. Crothers DNA sequence specificity of mitomycin cross-linking Biochemistry 28 1989 3901 3907 (Pubitemid 19125440)
31. M.F. Weidner, J.T. Millard, and P.B. Hopkins Determination at single nucleotide resolution of the sequence specificity of DNA interstrand crosslinking agents in DNA fragments J. Am. Chem. Soc. 111 1989 9270 9272 (Pubitemid 20066198)
32. J.T. Millard, M.F. Weidner, S. Raucher, and P.B. Hopkins Determination of the DNA crosslinking sequence specificity of reductively activated mitomycin C at single-nucleotide resolution: deoxyguanosine residues at CpG are crosslinked preferentially J. Am. Chem. Soc. 112 1990 3637 3641 (Pubitemid 20305709)
33. I.N. White, and A.R. Mattocks Reaction of dihydropyrrolizines with deoxyribonucleic acids in vitro Biochem. J. 128 1972 291 297
34. R.L. Reed, K.G. Ahern, G.D. Pearson, and D.R. Buhler Crosslinking of DNA by dehydroretronecine, a metabolite of pyrrolizidine alkaloids Carcinogenesis 9 1988 1355 1361
35. T.W. Petry, G.T. Bowden, R.J. Huxtable, and I.G. Sipes Characterization of hepatic DNA damage induced in rats by the pyrrolizidine alkaloid monocrotaline Cancer Res. 44 1984 1505 1509 (Pubitemid 14125887)
36. J. Woo, S.T. Sigurdsson, and P.B. Hopkins DNA interstrand cross-linking reactions of pyrrole-derived, bifunctional electrophiles: evidence for a common target site in DNA J. Am. Chem. Soc. 115 1993 3407 3415 (Pubitemid 23173832)
37. P.P. Wickramanayake, B.L. Arbogast, D.R. Buhler, M.L. Deinzer, and A.L. Burlingame Alkylation of nucleosides and nucleotides by dehydroretronecine; characterization of covalent adducts by liquid secondary ion mass spectrometry J. Am. Chem. Soc. 107 1985 2485 2488
38. W.K. Anderson Activity of bis-carbamoylmethyl derivatives of pyrrole and pyrrolizines against human tumor xenografts in nude mice Cancer Res. 42 1982 2168 2170 (Pubitemid 12121426)
39. W.K. Anderson, C.P. Chang, P.F. Corey, M.J. Halat, A.N. Jones, H.L. McPherson Jr., J.S. New, and A.C. Rich Vinylogous carbinolamine tumor inhibitors. 8. Activity of bis(acyloxymethyl) derivatives of pyrroles and pyrrolizines against a panel of murine leukemias and solid tumors Cancer Treat. Rep. 66 1982 91 97 (Pubitemid 12254671)
40. V.J. Stella, W.K. Anderson, A. Benedetti, W.A. Waugh, and R.B. Killion Jr. Stability of carmethizole hydrochloride (NSC-602668), an experimental cytotoxic agent Int. J. Pharm. 71 1991 157 165
41. W.L. Elliott, D.W. Fry, W.K. Anderson, J.M. Nelson, K.E. Hook, P.A. Hawkins, and W.R. Leopold III In vivo and in vitro evaluation of the alkylating agent carmethizole Cancer Res. 51 1991 4581 4587
42. W.R. Waud, J. Plowman, S.D. Garrison Jr., D.J. Dykes, W.K. Anderson, and D.P. Griswold Jr. Antitumor activity and cross-resistance of carmethizole hydrochloride (NSC 602668) in preclinical models in mice Cancer Chemother. Pharmacol. 30 1992 261 266
43. K. Sanjiv, T.L. Su, S. Suman, R. Kakadiya, T.C. Lai, H.Y. Wang, M. Hsiao, and T.C. Lee The novel DNA alkylating agent BO-1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models Int. J. Cancer 130 2011 1440 1450
44. L. Kelland The resurgence of platinum-based cancer chemotherapy Nat. Rev. Cancer 7 2007 573 584 (Pubitemid 47106628)
45. G.W. Sledge, D. Neuberg, P. Bernardo, J.N. Ingle, S. Martino, E.K. Rowinsky, and W.C. Wood Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J. Clin. Oncol. 21 2003 588 592 (Pubitemid 46621890)
46. L.D. Mayer, and A.S. Janoff Optimizing combination chemotherapy by controlling drug ratios Mol. Interventions 7 2007 216 223 (Pubitemid 47437268)
47. P.C. Lee, R. Kakadiya, T.L. Su, and T.C. Lee Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells Neoplasia 12 2010 376 387
48. P.C. Lee, H.J. Lee, R. Kakadiya, K. Sanjiv, T.L. Su, and T.C. Lee Multidrug-resistant cells overexpressing P-glycoprotein are susceptible to DNA crosslinking agents due to attenuated Src/nuclear EGFR cascade-activated DNA repair activity Oncogene 32 2013 1144 1154
49. R. Morphy, and Z. Rankovic Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 48 2005 6523 6543 (Pubitemid 41504710)
50. P.G. Baraldi, A.N. Zaid, D. Preti, F. Fruttarolo, M.A. Tabrizi, A. Iaconinoto, M.G. Pavani, M.D. Carrion, C.L. Cara, and R. Romagnoli Hybrid molecules based on distamycin A as potential antitumor agents Arkivoc 7 2006 20 34 (Pubitemid 43049359)
51. M. Decker Hybrid molecules incorporating natural products: applications in cancer therapy, neurodegenerative disorders and beyond Curr. Med. Chem. 18 2011 1464 1475
52. P.G. Baraldi, R. Romagnoli, A.E. Guadix, M.J. Infantas, M.A. Gallo, A. Espinosa, A. Martinez, J.P. Bingham, and J.A. Hartley Design, synthesis, and biological activity of hybrid compounds between uramustine and DNA minor groove binder distamycin A J. Med. Chem. 45 2002 3630 3638 (Pubitemid 34856103)
53. V.A. Bacherikov, T.C. Chou, H.J. Dong, X. Zhang, C.H. Chen, Y.W. Lin, T.J. Tsai, R.Z. Lee, L.F. Liu, and T.L. Su Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity Bioorg. Med. Chem. 13 2005 3993 4006 (Pubitemid 40725031)
54. N. Kapuriya, K. Kapuriya, X. Zhang, T.C. Chou, R. Kakadiya, Y.T. Wu, T.H. Tsai, Y.T. Chen, T.C. Lee, A. Shah, Y. Naliapara, and T.L. Su Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage Bioorg. Med. Chem. 16 2008 5413 5423 (Pubitemid 351694491)
55. R. Kakadiya, H. Dong, A. Kumar, N. Dodiya, N. Kapuriya, X. Zhang, T.C. Chou, T.C. Lee, A. Shah, and T.L. Su Potent DNA-directed alkylating agents. Synthesis and biological activity of phenyl N-mustard-quinoline conjugates having a urea or hydrazine carboximide linker, synthesis and biological activity Bioorg. Med. Chem. 18 2010 2285 2299
56. K.R. Hande Etoposide: four decades of development of a topoisomerase II inhibitor Eur. J. Cancer 34 1998 1514 1521 (Pubitemid 28446331)
57. M. Stiborová, J. Sejbal, D.L. Borek, D. Aimová, J. Poljaková, K. Forsterová, M. Rupertová, J. Wiesner, J. Hudecek, M. Wiessler, and E. Frei The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide Cancer Res. 64 2004 8374 8380 (Pubitemid 39496831)
58. F. Leteurtre, J. Madalengoitia, A. Orr, T.J. Cuzi, E. Lehnert, T. Macdonald, and Y. Pommier Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin Cancer Res. 52 1992 4478 4484
59. S.D. Cline, T.L. Macdonald, and N. Osheroff Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine Biochemistry 36 1997 13095 13101 (Pubitemid 27465425)